|
1
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:2140–2141. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Quaresma M, Coleman MP and Rachet B:
40-year trends in an index of survival for all cancers combined and
survival adjusted for age and sex for each cancer in England and
Wales, 1971–2011: A population-based study. Lancet. 385:1206–1218.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maron R, Schechter B, Mancini M,
Mahlknecht G, Yarden Y and Sela M: Inhibition of pancreatic
carcinoma by homo- and heterocombinations of antibodies against
EGF-receptor and its kin HER2/ErbB-2. Proc Natl Acad Sci USA.
110:15389–15394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen YL, Hu CM, Hsu JT, Chang CC, Huang
TY, Chiang PH, Chen WY, Chang YT, Chang MC, Tien YW, et al:
Cellular 5-hydroxylmethylcytosine content determines tumorigenic
potential and prognosis of pancreatic ductal adenocarcinoma. Am J
Cancer Res. 8:2548–2563. 2018.PubMed/NCBI
|
|
6
|
Capello M, Vykoukal JV, Katayama H, Bantis
LE, Wang H, Kundnani DL, Aguilar-Bonavides C, Aguilar M, Tripathi
SC, Dhillon DS, et al: Exosomes harbor B cell targets in pancreatic
adenocarcinoma and exert decoy function against complement-mediated
cytotoxicity. Nat Commun. 10:2542019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chu LC, Goggins MG and Fishman EK:
Diagnosis and detection of pancreatic cancer. Cancer J. 23:333–342.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ilic M and Ilic I: Epidemiology of
pancreatic cancer. World J Gastroenterol. 22:9694–9705. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vogelstein B, Papadopoulos N, Velculescu
VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes.
Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin QJ, Yang F, Jin C and Fu DL: Current
status and progress of pancreatic cancer in China. World J
Gastroenterol. 21:7988–8003. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yan X, Wan H, Hao X, Lan T, Li W, Xu L,
Yuan K and Wu H: Importance of gene expression signatures in
pancreatic cancer prognosis and the establishment of a prediction
model. Cancer Manag Res. 11:273–283. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang G, Schetter A, He P, Funamizu N,
Gaedcke J, Ghadimi BM, Ried T, Hassan R, Yfantis HG, Lee DH, et al:
DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity
and predicts clinical outcome in pancreatic ductal adenocarcinoma.
PLoS One. 7:e315072012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou S, Liu P, Jiang W and Zhang H:
Identification of potential target genes associated with the effect
of propranolol on angiosarcoma via microarray analysis. Oncol Lett.
13:4267–4275. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang H and Brekken RA: The next wave of
stroma-targeting therapy in pancreatic cancer. Cancer Res.
79:328–330. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Heinemann V, Reni M, Ychou M, Richel DJ,
Macarulla T and Ducreux M: Tumour-stroma interactions in pancreatic
ductal adenocarcinoma: rationale and current evidence for new
therapeutic strategies. Cancer Treat Rev. 40:118–128. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang G, He P, Tan H, Budhu A, Gaedcke J,
Ghadimi BM, Ried T, Yfantis HG, Lee DH, Maitra A, et al:
Integration of metabolomics and transcriptomics revealed a fatty
acid network exerting growth inhibitory effects in human pancreatic
cancer. Clin Cancer Res. 19:4983–4993. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang G, Schetter A, He P, Funamizu N,
Gaedcke J, Ghadimi BM, Ried T, Hassan R, Yfantis HG, Lee DH, et al:
DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity
and predicts clinical outcome in pancreatic ductal adenocarcinoma.
PLoS One. 7:e315072012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ling YH, Ren CH, Guo XF, Xu LN, Huang YF,
Luo JC, Zhang YH, Zhang XR and Zhang ZJ: Identification and
characterization of microRNAs in the ovaries of multiple and
uniparous goats (Capra hircus) during follicular phase. BMC
Genomics. 15:3392014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Raimondi S, Lowenfels AB, Morselli-Labate
AM, Maisonneuve P and Pezzilli R: Pancreatic cancer in chronic
pancreatitis; aetiology, incidence, and early detection. Best Pract
Res Clin Gastroenterol. 24:349–358. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Grippo PJ and Munshi HG: Imaging the
Pancreatic ECM. Pancreatic Cancer and Tumor Microenvironment.
Trivandrum (India): Transworld Research Network. Chapter 2.
2012
|
|
22
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Le A, Rajeshkumar NV, Maitra A and Dang
CV: Conceptual framework for cutting the pancreatic cancer fuel
supply. Clin Cancer Res. 18:4285–4290. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Apte MV, Pirola RC and Wilson JS:
Pancreatic stellate cells: A starring role in normal and diseased
pancreas. Front Physiol. 3:3442012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Koikawa K, Ohuchida K, Takesue S, Ando Y,
Kibe S, Nakayama H, Endo S, Abe T, Okumura T, Horioka K, et al:
Pancreatic stellate cells reorganize matrix components and lead
pancreatic cancer invasion via the function of Endo180. Cancer
Lett. 412:143–154. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Grzesiak JJ, Ho JC, Moossa AR and Bouvet
M: The integrin-extracellular matrix axis in pancreatic cancer.
Pancreas. 35:293–301. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Burridge K: Focal Adhesions: A personal
perspective on a half century of progress. FEBS J. 284:3355–3361.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ebrahimi S, Hosseini M, Shahidsales S,
Maftouh M, Ferns GA, Ghayour-Mobarhan M, Hassanian SM and Avan A:
Targeting the Akt/PI3K signaling pathway as a potential therapeutic
strategy for the treatment of pancreatic cancer. Curr Med Chem.
24:1321–1331. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zou WB, Tang XY, Zhou DZ, Qian YY, Hu LH,
Yu FF, Yu D, Wu H, Deng SJ, Lin JH, et al: SPINK1, PRSS1, CTRC, and
CFTR genotypes influence disease onset and clinical outcomes in
chronic pancreatitis. Clin Transl Gastroenterol. 9:2042018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Collins FS: Cystic fibrosis: Molecular
biology and therapeutic implications. Science. 256:774–779. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Anderson MP, Gregory RJ, Thompson S, Souza
DW, Paul S, Mulligan RC, Smith AE and Welsh MJ: Demonstration that
CFTR is a chloride channel by alteration of its anion selectivity.
Science. 253:202–205. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhu Q, Li H, Liu Y and Jiang L: Knockdown
of CFTR enhances sensitivity of prostate cancer cells to cisplatin
via inhibition of autophagy. Neoplasma. 64:709–717. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
De Lisle RC: Disrupted tight junctions in
the small intestine of cystic fibrosis mice. Cell Tissue Res.
355:131–142. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Munck A: Cystic fibrosis: Evidence for gut
inflammation. Int J Biochem Cell Biol. 52:180–183. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vij N, Mazur S and Zeitlin PL: CFTR is a
negative regulator of NFkappaB mediated innate immune response.
PLoS One. 4:e46642009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen J, Jiang XH, Chen H, Guo JH, Tsang
LL, Yu MK, Xu WM and Chan HC: CFTR negatively regulates
cyclooxygenase-2-PGE(2) positive feedback loop in inflammation. J
Cell Physiol. 227:2759–2766. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brereton MF, Iberl M, Shimomura K, Zhang
Q, Adriaenssens AE, Proks P, Spiliotis II, Dace W, Mattis KK,
Ramracheya R, et al: Reversible changes in pancreatic islet
structure and function produced by elevated blood glucose. Nat
Commun. 5:46392014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sun P, Zhu X, Shrubsole MJ, Ness RM,
Hibler EA, Cai Q, Long J, Chen Z, Li G, Hou L, et al: Genetic
variation in SLC7A2 interacts with calcium and magnesium intakes in
modulating the risk of colorectal polyps. J Nutr Biochem. 47:35–40.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen J, Yao Y, Gong C, Yu F, Su S, Chen J,
Liu B, Deng H, Wang F, Lin L, et al: CCL18 from tumor-associated
macrophages promotes breast cancer metastasis via PITPNM3. Cancer
Cell. 19:541–555. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bonnet S, Archer SL, Allalunis-Turner J,
Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta
L, Bonnet S, et al: A mitochondria-K+ channel axis is suppressed in
cancer and its normalization promotes apoptosis and inhibits cancer
growth. Cancer Cell. 11:37–51. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang YP, Huang LY, Sun WM, Zhang ZZ, Fang
JZ, Wei BF, Wu BH and Han ZG: Insulin receptor tyrosine kinase
substrate activates EGFR/ERK signalling pathway and promotes cell
proliferation of hepatocellular carcinoma. Cancer Lett. 337:96–106.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang L, Ma T and Zhang J: GPRC5A exerts
its tumor-suppressive effects in breast cancer cells by inhibiting
EGFR and its downstream pathway. Oncol Rep. 36:2983–2990. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang J, Farris AB, Xu K, Wang P, Zhang X,
Duong DM, Yi H, Shu HK, Sun SY and Wang Y: GPRC5A suppresses
protein synthesis at the endoplasmic reticulum to prevent
radiation-induced lung tumorigenesis. Nat Commun. 7:117952016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chey WY and Chang T: Neural hormonal
regulation of exocrine pancreatic secretion. Pancreatology.
1:320–335. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Vaziri-Gohar A, Zarei M, Brody JR and
Winter JM: Metabolic dependencies in pancreatic cancer. Front
Oncol. 8:6172018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rijkers AP, Bakker OJ, Ahmed Ali U,
Hagenaars JCJP, van Santvoort HC, Besselink MG, Bollen TL and van
Eijck CH;: Dutch Pancreatitis Study Group: Risk of pancreatic
cancer after a primary episode of acute pancreatitis. Pancreas.
46:1018–1022. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Theocharis AD, Skandalis SS, Gialeli C and
Karamanos NK: Extracellular matrix structure. Adv Drug Deliv Rev.
97:4–27. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Canobbio I, Balduini C and Torti M:
Signalling through the platelet glycoprotein Ib-V-IX complex. Cell
Signal. 16:1329–1344. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Eke I and Cordes N: Focal adhesion
signaling and therapy resistance in cancer. Semin Cancer Biol.
31:65–75. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Guo W and Giancotti FG: Integrin
signalling during tumour progression. Nat Rev Mol Cell Biol.
5:816–826. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lee JW and Juliano R: Mitogenic signal
transduction by integrin- and growth factor receptor-mediated
pathways. Mol Cells. 17:188–202. 2004.PubMed/NCBI
|
|
52
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Song G, Ouyang G and Bao S: The activation
of Akt/PKB signaling pathway and cell survival. J Cell Mol Med.
9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hers I, Vincent EE and Tavaré JM: Akt
signalling in health and disease. Cell Signal. 23:1515–1527. 2011.
View Article : Google Scholar : PubMed/NCBI
|
